Bioniche Converts a Portion of its Debt to Equity



    - results in US$1.75 million of new available funds -

    BELLEVILLE, ON, March 27 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC),
a research-based, technology-driven Canadian biopharmaceutical company, today
announced that the Company has exercised its right under the agreement to
repay US$1.75 million of its secured revolving credit facility with Valens
U.S. (formerly Laurus Master Funds) in common shares.
    The conversion is in accordance with the formula set out in the original
agreement signed in 2005. The shares will be priced at the ten day market
average less 15% which equates to 2,671,900 shares. In addition, the Company
will issue 200,000 five-year warrants at market price ($0.77 per share) in
exchange for Valens waiving certain volume restrictions relating to the
conversion under the agreement. There is no penalty attached to this
repayment.
    This conversion will result in new available funds of US$1.75 million. As
a result, the Company's capacity to borrow under the revolving credit facility
after the conversion will be approximately US$3.2M, determined by a formula
which measures existing levels of inventory and accounts receivable.
    "Again we appreciate the support and flexibility of our bankers, Valens
U.S.," said Patrick Montpetit, Chief Financial Officer of Bioniche Life
Sciences Inc. "This private placement will improve our liquidity as we
continue to execute our Phase III clinical development program with Urocidin
in bladder cancer and begin the construction of a facility in which to
scale-up production of our E. coli O157:H7 cattle vaccine in Belleville,
Ontario."

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
200 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. Bioniche has been named one of Canada's Top Ten Life Sciences
Companies for 2008. For more information, please visit www.Bioniche.com.

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00013159EF




For further information:

For further information: Jennifer Shea, Corporate Communications,
Investor & Government Relations Director, Bioniche Life Sciences Inc.,
Telephone: (613) 966-8058, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com

Organization Profile

Telesta Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890